Apeximmune Therapeutics
PrivateLast Round
Series A
Mar 31, 2025
Total Funding Raised
$27.7M
Company Overview
Apeximmune Therapeutics is a biotechnology company that develops novel biologics and therapeutic antibodies designed to modulate the immune system for the treatment of cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Apeximmune Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Apeximmune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 31, 2025 | ||||
| Grant | Jun 1, 2023 | ||||
| Seed | Mar 12, 2021 |
Apeximmune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant |
| DCI Partners | Series A |
| TA YA VENTURE HOLDINGS LIMITED | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 31, 2025
$21.3M raised in Series A funding.
Apeximmune Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Apeximmune Therapeutics's valuation, stock price, and market status.
